ACOX1

Hypha Discovery Limited, the leading specialist CRO for drug metabolite provision, and Cypex Limited, experts in the provision of recombinant xenobiotic metabolising enzymes, have formed a partnership wherein Hypha can scale-up and purify metabolites made by Cypex enzymes. Slough/Dundee, UK, 3rd February 2020 / Sciad Newswire / Hypha Discovery Limited , the leading specialist CRO for drug metabolite provision, and Cypex Limited , experts in the provision of recombinant xenobiotic metabolising enzymes, have formed a partnership wherein Hypha can scale-up and purify metabolites made by Cypex enzymes (available as Bactosomes ). The partnership utilises the expert services Hypha Discovery already provides to pharmaceutical and agrochemical clients using its One Stop Metabolite Shop . The one-stop shop comprises a combination of both biological and chemical techniques so clients can quickly establish a method to identify and scale up production of any type of metabolite to support R&D needs. Expanding this toolbox to include additional xenobiotic-metabolising enzymes developed by Cypex, provides Hypha with even more options for synthesising and purifying metabolite standards for clients. Cypex’s portfolio of recombinant enzymes is underpinned by patented technology which enables the expression of human and other mammalian drug-metabolising enzymes in bacteria. Access to Cypex’s enzymes augments the suite of PolyCYPs enzymes developed by Hypha scientists for accessing CYP derived metabolites. The partnership enables access to metabolites derived from CYP, FMO, AOX, UGT, SULT, CES, MOA enzymes from a variety of clinically relevant species, as well as humans. Liam Evans, CEO of Hypha Discovery, commented: “We are delighted to further develop our relationship with Cypex, which strengthens Hypha’s position as the go-to company for metabolites. We value this opportunity to collaborate with the team at Cypex and are excited by the synergies that this partnership brings . ” Michael Voice, Director of Cypex, added, “ There is an obvious synergy between Cypex’s enzyme products and Hypha’s expertise in metabolite production, purification and identification. Our customers will not only have access to a wider range of services, they are also assured of the excellent level of personal service that both Cypex and Hypha pride themselves upon. I am delighted to be working with the team at Hypha to better serve our customers. ” Ends For further information, contact: Corporate Contact: Hypha Discovery Limited Julia Shanu-Wilson, Head of Scientific Communications T: +44 (0)1753 568300 E: julia.shanuwilson@ hyphadiscovery.co.uk Cypex Limited Dr Michael Voice, Director T: +44 (0)1382 562391 E: mwvoice@cypex.co.uk PR Contact: Victoria Deaner / Deborah Cockerill Sciad Communications Ltd T: +44 (0)20 3405 7892 E: HyphaDiscovery@sciad.com Notes to Editors About Hypha Discovery Limited Hypha Discovery Ltd is a UK-based specialist CRO providing solutions to global pharmaceutical and agrochemical R&D partners through the production of mammalian and microbial metabolites, as well as expertise in microbially-derived natural products. We have delivered multiple metabolite projects for over 120 companies worldwide, including 7 of the top 10 pharma companies and 4 out of 5 of the top agrochemical companies. For more information, visit About Cypex Limited Cypex works with international pharmaceutical companies and world-leading academics to provide relevant tools to give reliable early insight during initial stage drug development and research studies. From its custom-built facilities in Dundee, its highly skilled team produce recombinant xenobiotic metabolising enzymes. Since the release of its first recombinant cytochrome P450 (CYP) in early 2000, Cypex has expanded its portfolio to more than 100 products covering pre-clinical species and human phase I and II drug-metabolising enzymes, fine chemicals for use as substrates, metabolite standards and inhibitors, and a range of antibodies. For more information, visit